InDex Pharmaceuticals Holding AB (OSTO:INDEX) ROCE % : -4.96% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is InDex Pharmaceuticals Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InDex Pharmaceuticals Holding AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -4.96%.

InDex Pharmaceuticals Holding AB ROCE % Historical Data

The historical data trend for InDex Pharmaceuticals Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InDex Pharmaceuticals Holding AB ROCE % Chart

InDex Pharmaceuticals Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-102.30

-72.81

-42.39

-25.99

-32.94

InDex Pharmaceuticals Holding AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-52.89	106.02	-41.53	-143.80	-4.96

InDex Pharmaceuticals Holding AB ROCE % Calculation

InDex Pharmaceuticals Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-95.038	/	( ( (351.336 - 14.735)	+	(299.389 - 58.906) )	/ 2 )
	=	-95.038	/	( (336.601	+	240.483)	/ 2 )
	=	-95.038	/	288.542
	=	-32.94 %

InDex Pharmaceuticals Holding AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-11.86	/	( ( (299.389 - 58.906)	+	(280.9 - 43.591) )	/ 2 )
	=	-11.86	/	( ( 240.483	+	237.309 )	/ 2 )
	=	-11.86	/	238.896
	=	-4.96 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

InDex Pharmaceuticals Holding AB (OSTO:INDEX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InDex Pharmaceuticals Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of InDex Pharmaceuticals Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InDex Pharmaceuticals Holding AB (OSTO:INDEX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Berzelius vag 13, Solna, SWE, 171 65

Website

https://www.indexpharma.com

InDex Pharmaceuticals Holding AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is being evaluated in the phase III study as a treatment for moderate to severe ulcerative colitis - a disabling, chronic inflammation of the colon. It has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences, with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Headlines

No Headlines